(12-10-20) Bamlanivimab, an outpatient infusion treatment, for patients with mild-to-moderate COVID-19, who are at high risk for progressing to severe COVID-19 and/or hospitalization, is available at Mercer Health.

Bamlanivimab is one of few outpatient treatment options and can be successful in preventing the need for hospitalization. As this medication needs to be given early in the illness, preferably within the first 7 days, patients, especially those at high risk, are urged to not wait until symptoms are severe, including shortness of breath, but rather contact their primary care provider to discuss if this treatment option is right for them.

Additional information can be found at https://mercer-health.com/covid-19-coronavirus-information.